AbbVie wagers up to $2B on Gilgamesh's approach to psychedelics – minus the trip
Phase 2License out/in
AbbVie is teaming up with Gilgamesh Pharmaceuticals in a deal worth up to $2 billion to develop a new class of drugs designed to treat psychiatric disorders without the psychoactive side effects that can be induced with first-generation psychedelics.
The pharma will harness Gilgamesh's research platform to create neuroplastogens that mimic the therapeutic potential of classic psychedelics, while avoiding hallucinations and eliminating the need for in-office administration and supportive care.
Already a heavyweight in neuroscience, AbbVie says there's still significant unmet need for people living with psychiatric disorders. "We know that to innovate in this field, we need to pursue novel technologies and approaches," said Jonathon Sedgwick, the company's global head of discovery research, adding that neuroplastogens could "pave the way for additional treatment approaches in psychiatry."
According to AbbVie, neuroplastogens target mechanisms that have shown potential to provide significant clinical benefits while minimising the challenging effects seen with first-generation psychedelics. Gilgamesh's platform leverages complex behavioural models, electrophysiology and molecular measures of neuroplasticity, while machine learning algorithms help to systematically map the bioactivity of psychoactive compounds.
AbbVie and Gilgamesh will research and develop a portfolio of next-generation therapeutics for psychiatric disorders. Gilgamesh will receive an upfront payment of $65 million and is eligible for up to $1.95 billion in option fees, milestones, and tiered royalties on net sales. Upon exercising its option, AbbVie will lead development and commercialisation activities.
Gilgamesh's internal pipeline features one neuroplastogen: GM-5022, an oral non-hallucinogenic compound in early development for depression and anxiety. Its two lead programmes are GM-1020, an oral NMDA receptor antagonist, as well as the short-acting 5-HT2A agonist5-HT2A agonist GM-2505, both of which have moved to Phase II in major depressive disorder. The company previously raised $27 million and $39 million in successive series A and B rounds.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.